William Blair Equities Analysts Increase Earnings Estimates for FibroGen, Inc. (NASDAQ:FGEN)
William Blair Equities Analysts Increase Earnings Estimates for FibroGen, Inc. (NASDAQ:FGEN)
FibroGen, Inc. (NASDAQ:FGEN – Get Rating) – Equities researchers at William Blair increased their Q3 2022 earnings per share estimates for shares of FibroGen in a note issued to investors on Monday, August 8th. William Blair analyst A. Hsieh now expects that the biopharmaceutical company will post earnings of ($0.58) per share for the quarter, up from their previous forecast of ($0.73). The consensus estimate for FibroGen's current full-year earnings is ($3.39) per share. William Blair also issued estimates for FibroGen's Q4 2022 earnings at ($0.55) EPS, FY2022 earnings at ($2.58) EPS, Q1 2023 earnings at ($0.53) EPS, Q2 2023 earnings at ($0.53) EPS, Q3 2023 earnings at ($0.52) EPS, Q4 2023 earnings at ($0.50) EPS, FY2023 earnings at ($2.07) EPS and FY2024 earnings at ($1.63) EPS.
FibroGen，Inc.(納斯達克：FDEN-GET評級)-威廉·布萊爾的股票研究人員在8月8日星期一發給投資者的一份報告中上調了對FibroGen股票2022年第三季度每股收益的預期。William Blair分析師A.Hsieh現在預計，這家生物製藥公司將公佈本季度每股收益(0.58美元)，高於此前預測的(0.73美元)。對FibroGen目前全年收益的普遍預期為每股3.39美元。威廉·布萊爾還發布了對FibroGen 2022年第四季度每股收益(0.55美元)、2022財年每股收益(2.58美元)、2023年第一季度每股收益(0.53美元)、2023年第二季度每股收益(0.53美元)、2023年第三季度每股收益(0.52美元)、2023年第四季度每股收益(0.50美元)、2023財年每股收益(2.07美元)和2024財年每股收益(1.63美元)的預期。
FibroGen (NASDAQ:FGEN – Get Rating) last announced its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.78) earnings per share for the quarter, topping the consensus estimate of ($0.94) by $0.16. FibroGen had a negative return on equity of 100.51% and a negative net margin of 83.64%. The firm had revenue of $29.81 million for the quarter, compared to the consensus estimate of $36.15 million. During the same period in the previous year, the business earned ($1.45) EPS. The firm's revenue for the quarter was up 22.3% on a year-over-year basis.
FibroGen(納斯達克：FDEN-GET評級)上一次公佈財報是在8月8日星期一。這家生物製藥公司公佈了本季度每股收益(0.78美元)，比普遍預期的(0.94美元)高出0.16美元。FibroGen的淨資產回報率為負100.51%，淨利潤率為負83.64%。該公司本季度營收為2981萬美元，而市場普遍預期為3615萬美元。去年同期，該業務的每股收益為1.45美元。該公司當季營收較上年同期增長22.3%。
FibroGen Price Performance
FibroGen性價比
Shares of FGEN stock opened at $14.05 on Thursday. FibroGen has a 1-year low of $7.81 and a 1-year high of $16.91. The stock's fifty day moving average price is $11.72 and its 200 day moving average price is $12.01. The company has a market cap of $1.31 billion, a price-to-earnings ratio of -5.93 and a beta of 0.87.
Fgen股票週四開盤報14.05美元。FibroGen的一年低點為7.81美元，一年高位為16.91美元。該股的50日移動均線價格為11.72美元，200日移動均線價格為12.01美元。該公司市值13.1億美元，市盈率為-5.93倍，貝塔係數為0.87。
Institutional Trading of FibroGen
FibroGen的機構交易
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Point72 Asset Management L.P. lifted its position in FibroGen by 235.9% during the 4th quarter. Point72 Asset Management L.P. now owns 3,732,594 shares of the biopharmaceutical company's stock worth $52,630,000 after acquiring an additional 2,621,494 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of FibroGen by 17.9% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 69,170 shares of the biopharmaceutical company's stock valued at $975,000 after buying an additional 10,521 shares during the period. Long Focus Capital Management LLC acquired a new position in shares of FibroGen in the 4th quarter valued at about $2,390,000. Fox Run Management L.L.C. acquired a new position in shares of FibroGen in the 4th quarter valued at about $231,000. Finally, Primecap Management Co. CA lifted its holdings in shares of FibroGen by 1.5% in the 4th quarter. Primecap Management Co. CA now owns 12,989,123 shares of the biopharmaceutical company's stock valued at $183,147,000 after buying an additional 197,366 shares during the period. Institutional investors and hedge funds own 77.35% of the company's stock.
機構投資者和對衝基金最近增持或減持了該公司的股份。Point72 Asset Management L.P.在第四季度將其在FibroGen的頭寸提高了235.9%。Point72 Asset Management L.P.在此期間額外收購了2,621,494股，目前擁有這家生物製藥公司3,732,594股股票，價值52,630,000美元。蘇黎世廣東銀行在第四季度增持了17.9%的FibroGen股票。Zurcher Kantonalbank蘇黎世廣東銀行現在持有這家生物製藥公司69,170股票，價值975,000美元，在此期間又購買了10,521股票。Long Focus Capital Management LLC在第四季度收購了FibroGen股票的新頭寸，價值約2390,000美元。福克斯Run Management L.L.C.在第四季度收購了FibroGen的新頭寸，價值約231,000美元。最後，Primecap Management Co.CA在第四季度增持了1.5%的FibroGen股票。PrimeCap Management Co.CA現在擁有這家生物製藥公司12,989,123股股票，價值183,147,000美元，在此期間又購買了197,366股。機構投資者和對衝基金持有該公司77.35%的股票。
FibroGen Company Profile
FibroGen公司簡介
(Get Rating)
(獲取評級)
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
FibroGen，Inc.是一家生物製藥公司，發現、開發和商業化治療嚴重未得到滿足的醫療需求的療法。該公司正在開發一種口服低氧誘導因子Pro羥基酶小分子抑制劑roxadustat，該藥已在美國、歐洲、中國和日本完成了治療慢性腎臟疾病貧血的第三階段臨牀開發，並在中國完成了治療與骨髓增生異常綜合徵相關的貧血的第二/第三階段臨牀開發。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on FibroGen (FGEN)
- Look at Honeywell for a Steady and Diversified Stock
- Why Invest in High-Yield Dividend Stocks?
- Find and Profitably Trade Stocks at 52-Week Lows
- Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
- Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
- 免費獲取StockNews.com關於FibroGen的研究報告(Fgen)
- 霍尼韋爾看好穩定和多元化的股票
- 為什麼要投資高收益股利股票？
- 找到並獲利於52周低點的股票交易
- 迪士尼(NYSE：DIS)的股票剛剛給了投資者一個巨大的信號
- 清潔能源法案通過後，太陽能股大放異彩
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.
接受FibroGen Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對FibroGen和相關公司的最新新聞和分析師評級的每日簡要摘要。